EICHORPublic-registry site landscape for NCT04822883, “Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia”, a Cognitive Impairment study sponsored by Recognify Life Sciences. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04822883 (registry record) |
| Study title | Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia |
| Official title | A Single-arm, Single-blind, Multiple Dose Study to Evaluate Safety and the Effects of RL-007 on Electroencephalograms and Event-related Potentials in Subjects With Schizophrenia |
| Sponsor | Recognify Life Sciences |
| Condition(s) | Cognitive Impairment; Schizophrenia |
| Phase | PHASE2 |
| Listed sites | 1 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT04822883.
Eichor generates a preliminary site-risk snapshot for NCT04822883 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Cognitive Impairment trials
More from Recognify Life Sciences
← Eichor home · All tracked trials · Cognitive Impairment studies · Weekly briefs
